We are live on
!
Find out more
LIM
Lagoda Investment Management Portfolio holdings
AUM
$182M
1-Year Est. Return
58.16%
This Fund
S&P 500
This Quarter
Est. Return
-4.01%
1 Year Est. Return
+58.16%
3 Year Est. Return
+249.95%
5 Year Est. Return
+282.35%
10 Year Est. Return
+2,138.78%
AUM
$291M
AUM Growth
-$41.3M
(-12%)
Cap. Flow
-$11M
Cap. Flow
% of AUM
-3.77%
Top 10 Holdings %
Top 10 Hldgs %
76.43%
Holding
41
New
12
Increased
7
Reduced
18
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Texas Pacific Land
TPL
|
+$1.95M |
| 2 |
VolitionRx Ltd
VNRX
|
+$659K |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$410K |
| 4 |
Microsoft
MSFT
|
+$372K |
| 5 |
Coca-Cola
KO
|
+$204K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SNMX
Senomyx, Inc.
SNMX
|
+$3.44M |
| 2 |
Baidu
BIDU
|
+$2.97M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$2.96M |
| 4 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
+$1.89M |
| 5 |
Precigen
PGEN
|
+$975K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 45.69% |
| 2 | Technology | 22.7% |
| 3 | Communication Services | 12.24% |
| 4 | Financials | 12.04% |
| 5 | Materials | 6.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
ExxonMobil
XOM
$696B
| $200K | 0.07% |
2,215
+1,500
| +210% | +$131K |
|
27
Brown-Forman Class B
BF.B
$12B
| $189K | 0.06% |
+6,575
| New | +$192K |
|
28
Johnson & Johnson
JNJ
$644B
| $161K | 0.06% |
+1,395
| New | +$161K |
|
29
Citigroup
C
$228B
| $137K | 0.05% |
+2,300
| New | +$124K |
|
30
Goldman Sachs
GS
$284B
| $115K | 0.04% |
+480
| New | +$97.5K |
|
31
SPDR Gold Trust
GLD
$145B
| $90K | 0.03% |
+900
| New | +$104K |
|
32
Intercontinental Exchange
ICE
$88.1B
| $90K | 0.03% |
+1,600
| New | +$88.6K |
|
33
Las Vegas Sands
LVS
$26.7B
| $85K | 0.03% |
+1,585
| New | +$92.4K |
|
34
ConocoPhillips
COP
$170B
| $62K | 0.02% |
1,231
| – | – |
|
35
Amazon
AMZN
$2.68T
| $60K | 0.02% |
+1,600
| New | +$62.7K |
|
36
Procter & Gamble
PG
$341B
| $60K | 0.02% |
+715
| New | +$60.9K |
|
37
Pfizer
PFE
$157B
| $40K | 0.01% |
1,292
-265
| -17% | -$8.09K |
|
38
AbbVie
ABBV
$465B
| $31K | 0.01% |
489
-2
| -0.4% | -$122 |
|
39
Abbott
ABT
$177B
| $25K | 0.01% |
639
-1
| -0.2% | -$40 |
|
40
Phillips 66
PSX
$106B
| $17K | 0.01% |
197
| – | – |
|
41
GSK
GSK
$100B
| – | – |
-139
| Closed | -$8K |
|
Similar funds
ECA
WMWM
TFG
PWA
FCP
ANC
COA
EWA
Lagoda Investment Management's Q4 2016 Portfolio in Review
As of Q4 2016, Lagoda Investment Management held 41 positions worth $291M, down 12% from $333M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Lagoda Investment Management withdrew a net $11M in Q4 2016, closing 1 position and reducing 18 holdings. Its most notable exit was GSK, an estimated $8K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 52% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Lagoda Investment Management opened a new position in Texas Pacific Land worth $2.06M.
- Lagoda Investment Management's largest Q4 2016 buy was Texas Pacific Land: 62,352 shares worth $2.06M.
- Lagoda Investment Management added most to VolitionRx Ltd in Q4 2016, an estimated $659K increase.
- Lagoda Investment Management's biggest Q4 2016 reduction was Senomyx, Inc., cutting an estimated $3.44M.
- Lagoda Investment Management fully exited GSK in Q4 2016, selling an estimated $8K.
- Lagoda Investment Management's ten largest holdings make up 76% of its $291M portfolio in Q4 2016.
- Lagoda Investment Management opened 12 new positions and closed 1 in Q4 2016.
- Lagoda Investment Management's portfolio value fell 12% quarter-over-quarter to $291M.
Based on Lagoda Investment Management's 13F filing for Q4 2016, filed 24 Jan 2017.